STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) are approved by FDA for all indications of reference products PROLIA® (denosumab) and XGEVA® (denosumab) respectively[1],[2]
SINGAPORE,March 4,2025-- OceanBase,a leading provider of multi-cloud distributed database systems,today announced a collaboration with Atome,Southeast Asia\'s largest buy-now-pay-later provider and a
NEW YORK,March 4,2025-- AIFIAN has released its 2024 Asia-Pacific investment report,highlighting key trends in liquor investment across the region. The findings reveal that Baijiu has emerged as the
BARCELONA,Spain,March 4,2025-- The global spotlight turned to the 2025 World Mobile Communications Congress (MWC),where FiberHome made a dazzling appearance under the theme "Connecting the Bright
NPT 2714 and NPT 2705 deliver increased network flexibility and investment protection TOKYO,March 4,2025--Ribbon Communications Inc. (Nasdaq: RBBN),a prominent supplier of real-time communications te
New offering delivers a composition workspace for students with educator-guided AI assistance,assignment-to-grading workflows and integrity insights - all in one place
